	US 12,263,213 B2
	Compositions for use in treatment of Chlamydia
Nadège Arnaud Barbe, Paris (FR); Leah Cole, Cambridge, MA (US); Andreas Karlsson, Paris (FR); Violette Sanchez, Paris (FR); and Timothy Tibbitts, Cambridge, MA (US)
Assigned to SANOFI PASTEUR, Lyons (FR)
Filed by SANOFI, Paris (FR)
Filed on Mar. 4, 2024, as Appl. No. 18/594,291.
Claims priority of provisional application 63/500,393, filed on May 5, 2023.
Claims priority of provisional application 63/449,571, filed on Mar. 2, 2023.
Claims priority of application No. 23305375 (EP), filed on Mar. 20, 2023; and application No. 23306372 (EP), filed on Aug. 11, 2023.
Prior Publication US 2024/0299524 A1, Sep. 12, 2024
Int. Cl. A61K 39/118 (2006.01); A61P 31/04 (2006.01); C07K 14/295 (2006.01); A61K 39/00 (2006.01)

CPC A61K 39/118 (2013.01) [A61P 31/04 (2018.01); C07K 14/295 (2013.01); A61K 2039/53 (2013.01); A61K 2039/70 (2013.01); C12N 2760/16134 (2013.01)]

38 Claims

1. A composition comprising:

(i) a nucleic acid comprising a nucleotide sequence encoding a modified Major Outer Membrane Protein (MOMP) polypeptide, wherein the modified MOMP polypeptide has an amino acid sequence comprising two or more conserved domain sequences of a native Chlamydia trachomatis MOMP polypeptide and a non-native loop sequence between the conserved domain sequences;

(ii) a nucleic acid that comprises a nucleotide sequence encoding a chimeric Chlamydia trachomatis MOMP variable domain (VD) polypeptide, wherein the chimeric MOMP VD polypeptide comprises an amino acid sequence comprising two or more Chlamydia trachomatis MOMP VD sequences of different serovars of Chlamydia trachomatis;

(iii) a nucleic acid that comprises a nucleotide sequence encoding a Chlamydia trachomatis CT443 polypeptide; and

(iv) a nucleic acid that comprises a nucleotide sequence encoding a Chlamydia trachomatis CT584 polypeptide.